PAK5 Antibody
Rabbit Polyclonal
$50.00 to US & $70.00 to Canada for most products. Final costs are calculated at checkout.
Background
The p21-activated kinases (PAKs) are serine-threonine kinases that bind to the active forms of Cdc42 and Rac. They are divided into two groups, the first of which include PAK1, 2 and 3, and can be activated by Cdc42/Rac binding. Group 1 PAKs contain an autoinhibitory domain whose activity is regulated by Cdc42/Rac binding. The group 1 PAKs are known to be involved in cellular processes such as gene transcription, apoptosis, and cell morphology and motility. Much less is known about the second group, which includes PAK4, 5 and 6. These proteins are not activated by Cdc42/Rac binding. PAK5 was initially identified as a kinase expressed primarily in brain that while possessing a kinase domain and GTPase binding domain similar to PAK4 and PAK6, is completely different from both. Expression of PAK5 in neural based cell lines resulted in neurite outgrowth suggesting that PAK5 may be involved in regulating the cytoskeletal changes necessary for promoting neurite outgrowth. Other experiments suggest that unlike the other PAKs, PAK5 may inhibit apoptosis by phosphorylating the Bcl-2 family member Bad.
Product Details
Target Details
Application Details
Formulation
Shipping & Handling
This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.